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Abstract Electrical activation of the carotid baroreceptor
system is an attractive therapy for the treatment of resistant
hypertension. In the past, several attempts were made to
directly activate the baroreceptor system in humans, but the
method had to be restricted to a few selected patients.
Adverse effects, the need for better electrical devices and
better surgical techniques, and the lack of knowledge about
long-term effects has greatly hampered developments in
this area for many years. Recently, a new and promising
device was evaluated in a multicenter feasibility trial, which
showed a clinically and statistically significant reduction in
office systolic blood pressure (>20 mm Hg). This reduction
could be sustained for at least 2 years with an acceptable
safety profile. In the future, this new device may stimulate
further application of electrical activation of the carotid




Lowering blood pressure to values below 140/90 mm Hg is
of great value for patients with essential hypertension. For
those with comorbidities such as diabetes mellitus or renal
impairment, the target should even be lower, but with the
available antihypertensive drugs, many patients either
cannot obtain full control of their hypertension with
medical therapy alone or cannot tolerate the adverse effects
of the treatment. Drug-resistant hypertension thus remains a
significant clinical problem in a number of patients, who
could benefit from alternative treatments such as electrical
activation of the carotid baroreceptors.
This review summarizes early observations on the
baroreceptor system and past experiments on electrical
activation of the carotid baroreceptor system. These
observations and experiments have contributed to our
current understanding of the baroreceptor system in the
regulation of blood pressure. It also discusses recent
experiences with a newly developed baropacing device,
which is still under investigation, and the future role of
carotid baroreflex activation therapy in the treatment of
hypertension and other diseases.
Acomprehensivesearchofdatabases(PubMed,MEDLINE,
and OLDMEDLINE) was performed, covering the years 1950
to 2009. The keywords carotid sinus, baroreflex, electrical
activation, hypertension,a n dangina pectoris were used in the
literature search. Reference lists in found articles were also
reviewed for other relevant articles. Articles in languages other
than English, French, German, or Dutch were excluded.
Early Observations on the Baroreceptor System
In 1836, Cooper [1] was among the first to describe the role
of the baroreceptor system in the regulation of blood
pressure. More than 85 years later, Hering [2] demonstrated
in dogs that electrical stimulation of the carotid sinus nerve
induced both bradycardia and hypotension, and that
transection of this nerve reversed these changes. He was
also able to show that bilateral transection of the carotid
sinus nerve resulted in systemic hypertension. Similar
results were reported later by Korner [3], who observed in
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output and heart rate) after bilateral transection of the
carotid nerves. Later on, several other investigators noted
that blood pressure became very unstable after denervation
of the baroreceptors. Taken together, their data suggested
that the primary function of the baroreceptor system is to
stabilize blood pressure and to prevent large, short-term
pressure fluctuations. Accordingly, Cowley, Liard, and
Guyton [4] proposed that the baroreflex system is not
important for the long-term regulation of blood pressure
and that previous data on the development of hypertension
after carotid sinus nerve denervation in animals had been
highly exaggerated, presumably as a result of methodologic
errors.
Nonetheless, interest in the role of the baroreceptor
system in hypertension has continued, and various methods
have been developed to challenge the system. These
methods include blocking the carotid sinus area using
procaine or lidocaine and stimulating it using epinephrine.
Other researchers have stimulated the carotid sinus area
using the neck cuff technique. With this device, it is
possible to create a negative pressure around the neck,
resulting in increased transmural pressure in the carotid
arteries. Such stimulation of the baroreceptor elicits
significant decreases in blood pressure, heart rate, and
cardiac output in both hypertensive and normotensive
subjects.
Kubicek and colleagues [5] wondered why the barore-
ceptor system fails to restore blood pressure to normal
levels in hypertensive patients. Using chronic splanchnic
nerve stimulation, they discovered the mechanism of
resetting of the baroreceptor system. Their data indicated
that it is possible for the baroreceptors and/or the central
nervous system pathways to adapt to chronically elevated
arterial blood pressure. Subsequently, electroneurographic
studies showed fewer impulses along the carotid sinus
nerve in dogs with renal hypertension than in normotensive
dogs [6]. These results implied that once the reflex was
reset, the baroreceptor system would act to maintain the
blood pressure at the elevated level.
Bristow and colleagues [7] showed that the baroreceptor
system in patients with hypertension not only is reset, but
also is less sensitive. They assessed baroreceptor sensitivity
based on the relationship between changes in systolic blood
pressure and changes in R-R intervals after intravenous
bolus injections of angiotensin II. Subsequently, several
research groups confirmed that the baroreceptor system is
less sensitive under conditions of elevated pressure. Angell-
James and George [8] concluded that, at least in rabbits, the
reduction in baroreceptor sensitivity is related more closely
to the duration of hypertension than to its severity. All these
data support the notion that the baroreflex system more or
less passively follows the development of hypertension and
that activation of the system is unlikely to produce
sustained reductions in blood pressure.
Early Experiments on Carotid Baroreflex Activation
Animal Experiments
Despite the foregoing, there has been ongoing interest in
devices to stimulate the baroreceptor system. Pioneering
work was done by Bilgutay and Lillehei [9], who designed
a compact, implantable device with two flat, discoid,
stainless steel electrodes that were attached directly to the
baroreceptor area and sutured in the wall of the carotid
arteries. The unit was triggered intermittently by R waves
picked up from the heart by an electrode. These inves-
tigators reported on the results of their experiments in four
groups of dogs: normotensive, acute neurogenic hyperten-
sive, renal hypertensive, and arteriosclerotic. Bilateral
electrical stimulation of the baroreceptor for 2 h caused a
drop in blood pressure in all dogs, but the best results were
seen in the hypertensive dogs, with decreases ranging from
28 to 100 mm Hg systolic and from 12 to 75 mm Hg
diastolic. Griffith and Schwartz [10] also designed an
implantable device with a bipolar electrode that was
attached directly to the carotid sinus nerve. They showed
that unilateral electrical stimulation in normotensive and
renal hypertensive dogs (with or without sectioning of the
contralateral carotid sinus nerve) reduced blood pressure in
all animals. After the stimulation was discontinued, blood
pressure quickly returned to baseline levels. A few years
later, Neistadt and Schwartz [11] reported similar results in
14 adult dogs with experimentally induced hypertension.
They applied an implantable carotid sinus nerve stimulator
with two electrodes and an external rechargeable trans-
mitter. On the day of implantation, a 36% decrease of mean
arterial pressure was measured. During the first month,
three dogs died and five extracted their stimulator, so only
six dogs were evaluated at 1 month. The average decrease
in mean arterial pressure with carotid nerve stimulation was
30%. After 2 months, three dogs could be evaluated; at that
time, the average decrease in pressure was 23%.
In 1969, Agishi and colleagues [12] reported on their
experiments with carotid sinus nerve stimulation in mongrel
dogs. Direct stimulation caused a drop in blood pressure in
all normotensive and hypertensive dogs. Chronic stimula-
tion was applied in eight hypertensive dogs and all
responded well. Other researchers have also shown a
reduction in blood pressure in animals subjected to carotid
sinus nerve stimulation. From these experiments, one can
conclude that stimulation of the carotid baroreceptor or
carotid sinus nerve can, indeed, lower blood pressure, at
least in experimental animals.
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Carlsten and colleagues [13] were the first to report on the
effects of brief episodes of direct carotid sinus stimulation
in humans. They studied five patients with neck cancer, in
whom the cancer process made a dissection of the carotid
sinus region necessary. Their findings were identical to
those obtained in the animal experiments. Electrical
stimulation of the carotid sinus nerve caused a typical
response, with a prompt fall in mean blood pressure, pulse
amplitude, and heart rate. In 1966, Bilgutay and Lillehei
[14] reported on the results of the first two patients who
were treated with an electronic implantable device for up to
12 months. These patients experienced an immediate and
significant reduction in blood pressure of 70/35 and 100/
40 mm Hg. In the first patient, blood pressure remained at
the lower level, but in the second patient, the pressure
tended to return towards baseline levels. At about the same
time, Schwartz and colleagues [15] published their results
on chronic electrical stimulation of the carotid sinus nerve
in 11 humans. Eight patients, who had been subjected to
carotid sinus nerve stimulation for periods varying between
5 months and 2½ years, were treated successfully, with a
sustained reduction in blood pressure of 30 to 100 mm Hg
systolic and 24 to 80 mm Hg diastolic. Two patients
responded only minimally and one died of renal failure
2 months postoperatively.
Since these initial observations, several investigators
have applied electrical activation of the baroreceptor system
in patients with resistant hypertension and those with severe
angina pectoris. Altogether, 64 cases of chronic electrical
activation of the baroreceptor system in the treatment of
hypertension have been reported (Table 1)[ 14–35]. In 44 of
these, significant reductions in blood pressure were shown,
ranging from 15 to 130 mm Hg systolic and from 10 to
80 mm Hg diastolic, with follow-up periods ranging from 1
to 37 months. In one study with three patients, the follow-
up period was not specified [20]. Of these 44 responsive
patients, 8 no longer received any antihypertensive drugs
[15, 28]. Two other patients had a minimal response [15]
and two patients had no response at all [31]. Most of the
remaining 16 patients had a favorable response initially, but
they died, stopped treatment, or were lost to follow-up
within 3 months after implantation: two died because of
stroke, three because of renal failure, two because of
pulmonary embolism, and one because of hyperkalemia
and ventricular arrhythmia [14, 15, 27–29, 35]. For two
patients, the cause of death was not identified [24, 29].
Three patients stopped treatment because of serious side
effects, one patient required removal of the stimulator, and
two patients were lost to follow-up [15, 29, 32].
In 1967, Braunwald and colleagues [36] first reported
the relief of angina pectoris by electrical activation of the
baroreceptor system in humans. Because the oxygen
requirements of the heart are directly related to heart rate,
the inotropic state of the myocardium, and intraventricular
pressure, these authors felt that if these factors could be
reduced, the oxygen demands of the heart would also be
diminished, resulting in a decrease in the incapacitating
symptoms of angina. In total, 135 cases of chronic electrical
stimulation in the treatment of angina pectoris have been
reported in the literature, with significant relief of pain
Table 1 Early publications on electrical activation of the carotid baroreceptor system in treating hypertension
Year Study Earlier publications on same patients Patients, n Follow-up, mo Blood pressure results
1966 Bilgutay & Lillehei [14] – 2 12 1, significant ↓; 1, lost to follow-up
1967 Schwartz et al. [15] – 11 5–30 6, significant ↓; 2, minimal response;
3, lost to follow-up
1968 Khatri & Cohn [20] – 3 Unknown 3, significant ↓
1969 Parsonnet et al. [21] Rothfeld et al. [23] 1 3 1, significant ↓
1969 Warembourg et al. [24] – 35 –8 2, significant ↓; 1, lost to follow-up
1970 Kaufmann et al. [26] – 1 1 1, significant ↓
1970 Torresani et al. [27] Jouve [19]; Torresani et al. [17, 18]3 1 2 –15 2, significant ↓; 1, lost to follow-up
1972 Brest et al. [28] Brest [25]8 7 –16 6, significant ↓; 2, lost to follow-up
1972 Tuckman et al. [29] Reich [22]; Tuckman et al. [16]1 2 4 –37 7, significant ↓; 5, lost to follow-up
1973 Both et al. [30] – 1 6 1, significant ↓
1973 Ernst et al. [31] – 55 –10 3, significant ↓; 2, no response
1973 Wagner et al. [32] – 52 –18 4, significant ↓; 1, lost to follow-up
1975 Solti et al. [33] – 1 13 1, significant ↓
1977 Myers [34] – 1 96 1, significant ↓
1980 Saadjian et al. [35] – 71 0 –36 5, significant ↓; 2, lost to follow-up
↓—decrease.
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1 to 132 months. Fourteen patients died; for nine of these,
the cause of death (eg, bradycardia, ventricular fibrillation,
heart failure, myocardial infarction, or pulmonary infarction)
was related to the procedure.
Problems and Side Effects
Despite the initial positive and promising results, electrical
activation of the baroreceptor system has remained restricted
to a carefully selected group of patients in only a few
institutions. Developments in this area probably were
hampered by the simultaneous introduction of more effective
and better tolerated antihypertensive drugs, but several
questions also remain unanswered and several problems are
unresolved. One of these is where the electrodes should be
placed. In most of the humans treated, the electrodes were
placedonthecarotidsinusnerves,eventhoughexperimentsin
animals with placement of the electrodes on the carotid
baroreceptors also showed good results. No advantages or
disadvantages for a certain position of the electrodes were
mentioned in the literature, but a nerve seems more fragile
than an artery, and risks for trauma and devascularization are
greater with dissection of the nerve than with dissection of the
artery. Limitations of surgical techniques at that time were
another problem; better techniques were necessary to limit the
risks and shorten the duration of the implant procedure.
Determining the best site of stimulation is another
problem. Parsonnet and colleagues [37] showed similar
effects on blood pressure with bilateral nerve stimulation or
unilateral stimulation of the most responsive nerve. In
contrast, Schwartz and colleagues [15] demonstrated that
bilateral stimulation was more effective than the summation
of the pressure reduction resulting from unilateral stimulation
of the two nerves. It is difficult to determine the most
responsive nerve preoperatively, and differences in respon-
siveness could also occur as a result of surgical trauma.
Another problem is the system of stimulation. In an
open-loop system, the duration, frequency, and amplitude
of impulses must be fixed after testing to find out the
optimal adjustments. Possible changes in the sensitivity of
the baroreceptors or the effect of the stimulation are not
taken into consideration because there is no feedback of the
actual cardiovascular status to the stimulator. From this
point of view, the introduction of a feedback loop can
improve the possibilities of electrical activation of the
baroreceptor system [38]. In experimental studies, where
closed-loop stimulation has been compared with open-loop
stimulation, all patients achieved similar hemodynamic
results, but a lower intensity of stimulation was required
in the closed-loop stimulation system [39].
A final problem is the long-term effect of the procedure.
Muchuncertainty remains regardingdamageanddegeneration
of the sinusnerve fibers, along withnerve fatigue andresetting
of the baroreceptor mechanism after a long period of electrical
stimulation. In addition, little is known about long-term effects
on the function of the heart and other organs. Proper
investigation of chronic stimulation is important to evaluate
the long-term effects of baroreceptor system stimulation.
Besides these problems, the reported side effects may have
hampered developments in this area. The most obvious effect
is the occurrence of pain in the mandible, teeth, external
auditory canals, throat, and chest, as well as in the post-
auricular,posteriorneck,andsuboccipitalregions[12, 15, 28–
30, 40]. Also, adverse effects as dysphonia, dysphagia,
hyperpnea, tachypnea, laryngospasm, gagging, coughing,
edema around the electrodes, and hypotension have been
reported [15, 22, 29, 41, 42]. These effects were caused by
nonoptimal settings of the stimulator, leakage or spread of
the electrical signal from the electrodes, and improper
positioning of the electrodes. Improper positioning can
weaken or disturb the electrical signals [15, 43]. It also can
lead to stimulation of muscle fibers or motor nerves, with
subsequent contraction of adjacent muscles [12, 40].
Recent Experiences and Developments
Recently, the sympathetic nervous system has moved
toward the center of cardiovascular medicine, because it
seems to be a key factor in the genesis of essential
hypertension [44]. More and more research strongly
suggests that the baroreceptors play a role in the long-
term control of arterial pressure [45]. As a result, interest is
growing in antihypertensive therapies with beneficial
effects on hypertension-related sympathetic activation [46,
47]. In 2004, Lohmeier et al. [48] published the results of a
study of prolonged activation of the baroreflex. He showed
sustained hypotension in six dogs that were subjected to
continuous carotid baroreceptor stimulation for 7 days.
With these results and today’s improved surgical techniques
and microelectronics, it is time to reevaluate the possible
role of electrical carotid baroreflex activation in treating
patients with resistant hypertension.
The Rheos Baroreflex Hypertension Therapy System
(CVRx, Inc.; Minneapolis, MN, USA) recently became
available. Detailed descriptions of this device and the
surgical technique used have been previously published
[49, 50￿￿]. In general, the Rheos System uses bilateral
carotid artery stimulation with an open-loop system. The
device is totally implantable, consisting of a pulse generator
and two leads. It uses modern microelectronics and a
special lead design for chronic electrical activation of the
carotid sinus baroreflex to reduce blood pressure. The two
leads conduct the activation energy from the pulse
generator to the baroreceptors located on the left and right
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pulse generator, making it possible to noninvasively control
the delivery of the activation energy. The device has
independent output circuits for the left and right leads,
and four independent therapies can be programmed, to
optimize the performance. Each therapy has independent
control of start and stop times, ramp function, dose settings,
burst settings, pulse amplitude, pulse width, pulse frequency,
and therapy pathway.
In 2003, 11 normotensive patients undergoing carotid
endarterectomy were enrolled in the Baroreflex Activation
System Study (BRASS) [51￿]. The carotid sinus barore-
ceptors were briefly stimulated under local or general
anesthesia through 1-minute incremental intervals. This
study demonstrated an average decrease in systolic blood
pressure from 144 mm Hg to 131 mm Hg, directly related
to the intensity of stimulation. Chronic experimental
application in humans is the next step.
A case report recently described a patient with malignant
hypertension who was successfully treated with the chronic
implantable Rheos System [52￿￿]. Now, results from a
multicenter feasibility study are available; participants
with treatment-resistant hypertension underwent implan-
tation of the Rheos System. This study shows an
acceptable safety profile and a clinically and statistically
significant reduction in office blood pressure of over
20 mm Hg systolic after 3 months of stimulation in 37
participants. A cohort of 17 participants was observed for
up to 2 years and it was found that the blood pressure
reduction could be sustained.
Future Perspectives
This new device may stimulate further research into the
applicability of electrical activation of the carotid baroreflex,
not only for treatment-resistant hypertension but also for
related cardiovascular disorders. Studies are now being
undertaken to evaluate baropacing in patients with conges-
tive heart failure. Angina pectoris may be another area where
the device could be useful.
Of course, many problems still must be addressed. Apart
from technical issues, these relate to the optimal use of the
system. For instance, we do not know which settings will
give the best results. Currently, frequency and voltage are
set empirically, but there may be more dynamic ways to
stimulate the baroreceptor system. We need to find out how
we can best modify the settings in relation to the circadian
pattern of blood pressure and heart rate. Also, it is unknown
whether both carotids must be paced or whether unilateral
stimulation will be effective. Beyond determining the
preferred settings, another challenge is creating a closed-
loop feedback system. A device that can monitor blood
pressure and stimulate the baroreceptor system as needed
would be a major breakthrough for patients with hitherto
refractory hypertension.
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